Collagen Lattice Model, Populated with Heterogeneous Cancer-Associated Fibroblasts, Facilitates Advanced Reconstruction of Pancreatic Cancer Microenvironment

• Published in: International journal of molecular sciences 2024-04, Vol.25 (7), p.3740
• Main Authors: Song, Xiaoyu, Nihashi, Yuma, Imai, Yukiko, Mori, Nobuhito, Kagaya, Noritaka, Suenaga, Hikaru, Shin-Ya, Kazuo, Yamamoto, Masamichi, Setoyama, Daiki, Kunisaki, Yuya, Kida, Yasuyuki S
• Format: Article
• Language: English
• Subjects: 3D tumor model; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell adhesion & migration; Cell differentiation; Collagen; drug screening; Fibroblasts; Gene expression; Humans; Hypoxia; Medical prognosis; Morphology; Pancreas; Pancreatic cancer; pancreatic ductal adenocarcinoma; Pancreatic Hormones; Pancreatic Neoplasms; Proline; Tumor Microenvironment
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25073740

Pancreatic ductal adenocarcinoma (PDAC) is a solid-tumor malignancy. To enhance the treatment landscape of PDAC, a 3D model optimized for rigorous drug screening is essential. Within the PDAC tumor microenvironment, a dense stroma comprising a large extracellular matrix and cancer-associated fibroblasts (CAFs) is well-known for its vital role in modulating tumor growth, cellular heterogeneity, bidirectional paracrine signaling, and chemoresistance. In this study, we employed a fibroblast-populated collagen lattice (FPCL) modeling approach that has the ability to replicate fibroblast contractility in the collagenous matrix to build dense stroma. This FPCL model allows CAF differentiation by facilitating multifaceted cell-cell interactions between cancer cells and CAFs, with the differentiation further influenced by mechanical forces and hypoxia carried within the 3D structure. Our FPCL models displayed hallmark features, including ductal gland structures and differentiated CAFs with spindle shapes. Through morphological explorations alongside in-depth transcriptomic and metabolomic profiling, we identified substantial molecular shifts from the nascent to mature model stages and potential metabolic biomarkers, such as proline. The initial pharmacological assays highlighted the effectiveness of our FPCL model in screening for improved therapeutic strategies. In conclusion, our PDAC modeling platform mirrors complex tumor microenvironmental dynamics and offers an unparalleled perspective for therapeutic exploration.